

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
MSN LABORATORIES PRIVATE LTD.,  
and MSN PHARMACEUTICALS INC.,  
Petitioners,

v.

BAUSCH HEALTH IRELAND LIMITED,  
Patent Owner.

---

Case IPR2022-00722<sup>1</sup>  
Patent 7,041,786

---

**PETITIONER MYLAN PHARMACEUTICALS INC.'S  
MANDATORY CHANGE-OF-INFORMATION NOTICES  
37 C.F.R. § 42.8(a)(3)**

---

<sup>1</sup> IPR2023-00016 has been joined with this proceeding.

Petitioner Mylan Pharmaceuticals Inc. (Mylan) submits the following mandatory change-of-information notices for IPR2022-00722.

**A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged**

Petitioner Mylan Pharmaceuticals Inc. is a co-defendant with Mylan Laboratories Ltd., Agila Specialties Inc, Mylan API US LLC, Mylan Inc., and Viatrix Inc. in parallel litigation. Additionally, Viatrix Inc. and Mylan Inc. are parent companies of Mylan Pharmaceuticals Inc.

**B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Unchanged**

Bausch asserted the involved patent in *Bausch Health Ireland Ltd. v. Mylan Laboratories Ltd.*, 2:21-cv-573 (WDPA) (administratively closed); 1:22-cv-00020-TSK (NDWV) (5-day trial set for June 17, 2024); and in *Bausch Health Ireland Ltd. v. MSN Labs.*, 2:21-cv-10057-SRC (DNJ) (third-party litigation: Mylan is not involved; no trial date set).

IPR2022-01102, IPR2022-01103, IPR2022-01104, and IPR2022-01105 involve later patents related to the challenged patent.

**C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – REVISED**

<b>Lead Counsel</b>	<b>Back-Up Counsel</b>
Jad Mills, No. 63,334 WILSON SONSINI GOODRICH & ROSATI 701 Fifth Avenue, Suite 5100 Seattle, WA 98104 Tel.: 206-883-2554 Fax: 206-883-2699 Email: <a href="mailto:jmills@wsgr.com">jmills@wsgr.com</a>	Richard Torczon, Reg. No. 34,448 WILSON SONSINI GOODRICH & ROSATI 1700 K Street N.W., 5th Floor, Washington, DC 20006-3817 Tel.: 202-973-8811 Fax: 866-947-7329 Email: <a href="mailto:rtorczon@wsgr.com">rtorczon@wsgr.com</a>
<b>Back-Up Counsel</b>	<b>Back-Up Counsel (New)</b>
Dennis Gregory, Reg. No. 52,967 WILSON SONSINI GOODRICH & ROSATI 900 South Capital of Texas Highway Las Cimas IV, Fifth Floor Austin, TX 78746-5546 Tel.: 512-338-5426 Fax: 512-338-5499 Email: <a href="mailto:dgregory@wsgr.com">dgregory@wsgr.com</a>	Tasha M. Thomas, Reg. No. 73,207 WILSON SONSINI GOODRICH & ROSATI 1700 K Street N.W., 5th Floor, Washington, DC 20006-3817 Tel.: 202-973-8883 Fax: 866-947-7329 Email: <a href="mailto:tthomas@wsgr.com">tthomas@wsgr.com</a>

**D. Electronic Service**

Petitioner consents to electronic service by email at the email addresses provided above and [4863-5899-2145@mail.vault.netdocuments.com](mailto:4863-5899-2145@mail.vault.netdocuments.com).

Respectfully submitted,

Date: March 3, 2023

/Jad A. Mills/  
Jad A. Mills, Reg. No. 63,344  
Counsel for Mylan Pharmaceuticals, Inc.

**CERTIFICATE OF SERVICE**

I certify that today this paper was served on the Patent Owner at the Patent Owner's email correspondence addresses as follows:

Justin J. Hasford	<a href="mailto:justin.hasford@finnegan.com">justin.hasford@finnegan.com</a>
Bryan C. Diner	<a href="mailto:bryan.diner@finnegan.com">bryan.diner@finnegan.com</a>
Joshua Goldberg	<a href="mailto:joshua.goldberg@finnegan.com">joshua.goldberg@finnegan.com</a>
Caitlin O'Connell	<a href="mailto:caitlin.o'connell@finnegan.com">caitlin.o'connell@finnegan.com</a>
Kyu Yun Kim	<a href="mailto:kyuyun.kim@finnegan.com">kyuyun.kim@finnegan.com</a>
Kassandra Officer	<a href="mailto:kassandra.officer@finnegan.com">kassandra.officer@finnegan.com</a>

and on MSN's counsel at:

Andrew Larsen	<a href="mailto:alarsen@merchantgould.com">alarsen@merchantgould.com</a>
Melissa Hayworth	<a href="mailto:mhayworth@merchantgould.com">mhayworth@merchantgould.com</a>

Date: March 3, 2023

Respectfully submitted,

/Robyn Moriarty/  
Robyn Moriarty